Pharmacoscopy for Patients with Refractory Primary Brain Tumors

Launched by UNIVERSITY OF ZURICH · Jan 27, 2025

Keywords

ClinConnect Summary

This clinical trial, titled "Pharmacoscopy for Patients with Refractory Primary Brain Tumors," is exploring a new way to personalize treatment for patients with hard-to-treat brain tumors, like glioblastoma and other rare brain cancers. The study uses advanced technology to help identify which drugs might work best for each individual patient. This means that instead of a one-size-fits-all approach, the treatment is tailored specifically to the patient's unique tumor characteristics.

To participate in this trial, patients must be 18 years or older and have a confirmed diagnosis of certain types of brain tumors that have not responded well to other treatments. They should also have a reasonable level of health and be able to follow the study's requirements. Participants can expect to undergo tests to see how their tumors respond to different medications and will receive support throughout the process. Importantly, the study is not yet recruiting participants, so those interested will need to wait for updates on when enrollment begins.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age 18 years or older on day of signing informed consent, female or male.
• • 2. Refractory glioblastoma, isocitrate dehydrogenase (IDH)-mutant astrocytoma or oligodendroglioma, histone-mutant glioma, ependymoma, medulloblastoma, meningioma or other rare primary brain tumor with a histological confirmation according to the WHO classification 2021. Primary tumors can be located at the cerebral or spinal level. Primary brain tumors with metastases outside of the brain may also be considered.
• • 3. Karnofsky performance status of 60 or more
• • 4. Life expectancy \>12 weeks.
• • 5. Limited systemic therapeutic options as per treating physician judgement. The number of previous lines of therapies is not limited.
• • 6. Surgery clinically indicated. A histological confirmation of the diagnosis of a recurrent brain tumor will be required before any treatment can be initiated.
• • 7. Adequate bone marrow, renal and hepatic function
• • 8. Ability to understand the requirements of the study, provide written informed consent and authorization of use and disclosure of protected health information, and agree to abide by the study restrictions and return for the required assessments.
• • 9. Written informed consent for study participation must be signed and dated by the patient and the investigator prior to any study-related intervention.
• Exclusion Criteria:
• • 1. Inability to undergo brain or spine MRI.
• • 2. Concurrent treatment with other systemic tumor-directed pharmacotherapies.
• • 3. Intent to be treated with radiotherapy.
• • 4. Any investigational antitumor therapy other than those under investigation in this study.
• • 5. Judgment by the investigator that the patient should not participate in the study because the patient is unlikely to comply with study procedures, restrictions and requirements.
• • 6. Intention to become pregnant during the course of the study or pregnancy. Women of childbearing potential, including women who had their last menstruation in the last 2 years, must have a negative urinary or serum pregnancy test.
• • 7. Women who are breast feeding and who do not agree to discontinue nursing prior to the first study treatment and for the period defined in the protocol.
• • 8. Sexually active men and women of childbearing potential who are not willing to use an effective contraceptive method during the study.